A study led by Gus Gazzard, consultant ophthalmologist at Moorfields Private, has shown that using a laser-based treatment on newly diagnosed cases of glaucoma is more successful and more cost-effective than the current method of using intraocular pressure lowering eye drops.
The announcement was covered by The Observer on Sunday 10 March with the headline: “Top surgeon hails fast procedure that saves a lifetime using eye drops.”
Glaucoma is the name given to conditions which involve increased pressure in the eye causing damage to the optic nerve. It can lead to misty and patchy vision and, if left untreated, can lead to loss of central vision. Glaucoma in some form affects approximately two percent of the UK population over 40 years of age and is one of the leading causes of blindness in the UK.
The three year trial, which is the largest ever of its kind, saw 718 patients newly-diagnosed with glaucoma or ocular hypertension (an increase in pressure in the eye without causing damage to the optic nerve) assigned one of two treatment pathways.
One pathway was the current standard treatment of administering eye drops designed to lower intraocular pressure (IOP) and the other involved a procedure called selective laser trabeculoplasty (SLT), an extremely quick procedure which is done in the clinic using anaesthetic eye drops and which lowers IOP by using lasers to increase the ease with which fluid can leave the eye.
The results showed that patients who received SLT were more regularly at the target IOP. There was also less chance of treatment escalation being required and a lower need for both glaucoma surgery and cataract extractions than was required by patients who received the eye drops.
The lead researcher on the study Mr Gus Gazzard, consultant ophthalmologist and glaucoma service director, said:
“In this study, we have shown that a simple, safe, pain-free laser treatment not only works better than eye-drops at preventing glaucoma from deteriorating but also costs the NHS less. These results strongly suggest that laser should be the first treatment for glaucoma in all newly diagnosed patients and will provoke further interest in its use in patients who are already on treatment.
“In the results so far we’ve already seen eye pressure lowering that has lasted far longer than the older early data had suggested, so we’re excited by the prospect of seeing very long-term pressure control given that glaucoma is a long-term, chronic disease.”
An ongoing follow up study funded by the NIHR HTA, alongside Moorfields Eye Charity, Fight for Sight, and the International Glaucoma Association, will provide more information on the long term effects. This follow up study is due to conclude in 2020.